Enhancement of Radiation Effects by Flavopiridol in Uterine Cervix Cancer Cells
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To determine the effects of combinations of radiation and flavopiridol, an inhibitor of cyclin-dependent kinases and global transcription, in a human uterine cervix cancer cell line. Materials and Methods: Human uterine cervix cancer cells (HeLa), cultured to the mid-log phase, were exposed to X-rays, flavopiridol, and combinations of X-rays and flavopiridol in various sequences. The end point in this study was the clonogenic survival, which was measured via clonogenic assays. In order to determine the intrinsic cytotoxicity of flavopiridol, 0, 5, 12.5, 25, 37.5, 50 and 100 nM of flavopiridol were added to cell culture media. In the combination treatment, four different schedules of flavopiridol and irradiation combinations were tested:treatment of flavopiridol for 24 hours followed by irradiation, simultaneous administration of flavopiridol and irradiation, and irradiation followed by flavopiridol (for 24 hours) at intervals of 6 and 24 hours. The fraction of cells surviving after the combination treatment with 2 Gy of radiation (SF2) was compared with that of the fraction of cells surviving after treatment with irradiation alone. Results: The cytotoxicity of flavopiridol was found to be dose-dependent, with an IC50 of 80 nM. No cytotoxic enhancements were observed when flavopiridol and radiation were administered simultaneously. Flavopiridol, administered either 24 hours before or 6 hours after irradiation, exerted no sensitizing effects on the cells. Only one protocol resulted in a radiosensitizing effect: the administration of flavopiridol 24 hours after irradiation. Conclusion: Flavopiridol enhanced the effects of radiation on a uterine cervix cancer cell line in vitro, and this enhancement was both sequence- and time-dependent
Abstract
Purpose: To determine the effects of combinations of radiation and flavopiridol, an inhibitor of cyclin-dependent kinases and global transcription, in a human uterine cervix cancer cell line. Materials and Methods: Human uterine cervix cancer cells (HeLa), cultured to the mid-log phase, were exposed to X-rays, flavopiridol, and combinations of X-rays and flavopiridol in various sequences. The end point in this study was the clonogenic survival, which was measured via clonogenic assays. In order to determine the intrinsic cytotoxicity of flavopiridol, 0, 5, 12.5, 25, 37.5, 50 and 100 nM of flavopiridol were added to cell culture media. In the combination treatment, four different schedules of flavopiridol and irradiation combinations were tested:treatment of flavopiridol for 24 hours followed by irradiation, simultaneous administration of flavopiridol and irradiation, and irradiation followed by flavopiridol (for 24 hours) at intervals of 6 and 24 hours. The fraction of cells surviving after the combination treatment with 2 Gy of radiation (SF2) was compared with that of the fraction of cells surviving after treatment with irradiation alone. Results: The cytotoxicity of flavopiridol was found to be dose-dependent, with an IC50 of 80 nM. No cytotoxic enhancements were observed when flavopiridol and radiation were administered simultaneously. Flavopiridol, administered either 24 hours before or 6 hours after irradiation, exerted no sensitizing effects on the cells. Only one protocol resulted in a radiosensitizing effect: the administration of flavopiridol 24 hours after irradiation. Conclusion: Flavopiridol enhanced the effects of radiation on a uterine cervix cancer cell line in vitro, and this enhancement was both sequence- and time-dependent
참고문헌 (13)
- "Cyclins, cyclin-dependentkinases and cdk inhibitors: implications in cell cyclecontrol and cancer.", 5, pp.127~56 (1995)
- "Expression of cell cycle control genes in human uterinecervical cancer cells", 32, pp.110~9 (2000)
- "Flavopiridol, the first cyclin-dependent kinaseinhibitor to enter the clinic: current status", 9, pp.2903~11 (2000)
- "Alteration of the phosphorylation stte of p34cdc2kinase by flavone L86-8275 in breast carcinoma cell. Correlationwith decreased H1 kinase activity"
- "Potent inhibition of CDC2 kinase activity by the flavonoidL86-8275", 201, pp.589~95 (1994)
- "Flavopiridol induces G1 arrest with inhibition of cyclindependentkinase (CDK) 2 and CDK4 in human breast carcinomacells.", 56, pp.2973~8 (1996)
- "Chemical inhibitors of cyclin-dependentkinases", 283, pp.113~28 (1997)
- "Growth inhibition with reversible cell cyclearrest of carcinoma cells by flavone L86-8275", 84, pp.1736~40 (1992)
- "Flavopiridolinversely affects p21(WAF1", CIP1) and p53 protects p21-sensitivecells from paclitaxel., 2002, pp.1, 420~5
- "Flavopiridolinduces cell cycle arrest and p53-independent apoptosisin non-small cell lung cancer cell lines", 5, pp.2925~38 (1999)
- "Flavopiridolinduces apoptosis in glioma cell lines independent ofretinoblastoma and p53 tumor suppressor pathway alterationsby a caspase-independent pathway", 2, pp.139~50 (2003)
- "Flavopiridol induces mitochondrialmediatedapoptosis in murine glioma GL261 cells via releaseof cytochrome c and apoptosis inducing factor", 2, pp.243~50 (2003)
- "Flavopiridol inhibits NF-κB activation induced by various carcinogens and inflammatory agentsthrough inhibition of IκBα and p65 phosphorylation", abrogatio(f cyclin d1)